Plasma cell leukemia (PCL) is a rare, aggressive subtype of multiple myeloma. Between 1973 and 2009, it’s estimated that PCL made up 0.6 percent of multiple myeloma diagnoses in the United States.
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma A transcriptomic classifier for PCL-like ...
Researchers show for the first time that engineered human plasma B cells can be used to treat a disease -- specifically leukemia -- in a humanized animal model. The results mark a key step in the ...
Current understanding of immune tolerance in cancer focuses on established tumours, but the critical early events that allow developing cancers to evade immune surveillance remain poorly understood.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback